Re: Karuna Therapeutics in dementia-related psychosis, and Axovant Gene therapy in PD
Jim: I continue to say I will add some shares in ACAD around 35.00 if it gets there. Your two stocks mentioned are way far away from any challenge to anything---especially the latter company. mentioned! Their track record is dubious. I like your first mention and put it on my watch list. But doesn't mean you can't make money in them. Just another waiting game for ACAD----brrrrr!!